Hemophagocytic lymphohistiocytosis (HLH) - a serious immune disease in children, mortality from which reaches forty percent. Against this background, damage to vital organs and tissues occurs, and for 20 years modern medicine has not been able to change mortality rates.

However, in a recent study, experts drew attention to the drug emapalumab, which managed to save the life of a child.

At the same time, the toxicity of the drug was less than that from the drugs currently used, and side effects were lower..

The study involved 34 patients, so it cannot be considered large enough to determine the effect of the drug on mortality from HLH. However, doctors consider the results promising..

“This is a very important progress.”. For the first time, we have a truly targeted way to treat HLH and a drug with a very low toxicity, ”says Dr. Michael Jordan, co-author of the study.

https: // www. medikforum. com /.

Keywords:.